Grand Pharmaceutical Group Limited has announced that its nuclear medicine R&D and production base in Wenjiang District, Chengdu, has secured a Class A "Radiation Safety License" from the Ministry of Ecology and Environment of China. This significant regulatory approval will allow the facility to commence operations in June. The base, which began construction in late 2022, has achieved rapid development milestones, breaking industry construction records. This facility is integral to Grand Pharmaceutical's strategic expansion in the fields of R&D, production, and sales of advanced anti-tumor technologies. The Group collaborates with organizations such as Sirtex Medical Pty Limited and Telix Pharmaceuticals Limited to enhance its tumor intervention and radionuclide-drug conjugate R&D platforms.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.